Views 394
Citations 0
June 2016

Complication of Autologous Stem Cell Transplantation in Retinitis Pigmentosa

Author Affiliations
  • 1Barbara and Donald Jonas Laboratory of Regenerative Medicine, Columbia University, New York, New York
  • 2Bernard and Shirlee Brown Glaucoma Laboratory, Department of Ophthalmology, Columbia University, New York, New York
  • 3Department of Ophthalmology, University of Montreal, Montreal, Quebec, Canada
  • 4Omics Laboratory, Department of Ophthalmology and Visual Science, University of Iowa, Iowa City

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Ophthalmol. 2016;134(6):711-712. doi:10.1001/jamaophthalmol.2016.0803

Advances in stem cell–mediated regenerative medicine have had a profound effect on interventional approaches to irreversible, blinding retinal diseases. In 2015,1 transplant of retinal pigment epithelial cells derived from human embryonic stem cells was shown to be safe in a phase 1/2 clinical trial for patients with age-related macular degeneration and Stargardt disease. Research involving induced pluripotent stem cells for retinal degenerative diseases also shows promise.2 Despite the potential of this therapeutic practice, many unregulated stem-cell treatments have emerged3 that may be harmful. We present a case of central retinal artery occlusion following autologous bone marrow peribulbar stem cell injection for retinitis pigmentosa.

First Page Preview View Large
First page PDF preview
First page PDF preview